Reuters logo
BRIEF-Roche says ocrelizumab reduced relapses and disability progression
2015年6月30日 / 凌晨5点07分 / 2 年前

BRIEF-Roche says ocrelizumab reduced relapses and disability progression

June 30 (Reuters) - Roche Holding Ag says positive results from two pivotal studies evaluating the investigational medicine ocrelizumab compared with interferon beta-1a Rebif), a standard-of-care therapy, in people with relapsing multiple sclerosis (MS), the most common form of the disease. The studies (called OPERA I and OPERA II) met their primary and major secondary endpoints. Further company coverage: (Reporting By Zurich Slot)

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below